We have shown that immunization with soluble recombinant chlamydial protease-like activity factor (rCPAF) and a T helper 1 type adjuvant can induce significantly enhanced bacterial clearance and protection against Chlamydia-induced pathological sequelae in the genital tract. In this study, we investigated the use of bone marrow derived dendritic cells (BMDCs) pulsed ex vivo with rCPAF + CpG in an adoptive subcutaneous immunization for the ability to induce protective immunity against genital chlamydial infection. We found that BMDCs pulsed with rCPAF + CpG efficiently up-regulated the expression of activation markers CD86, CD80, CD40, and major histocompatibility complex class II (MHC II), and secreted interleukin-12, but not IL-10 and IL-4. Mice adoptively immunized with rCPAF + CpG-pulsed BMDCs or UV-EB + CpG-pulsed BMDCs produced elevated levels of antigen-specific IFN-γ and enhanced IgG1 and IgG2a antibodies. Moreover, mice immunized with rCPAF + CpG-pulsed BMDCs or UV-EB + CpG-pulsed BMDCs exhibited significantly reduced genital Chlamydia shedding, accelerated resolution of infection, and reduced oviduct pathology when compared to infected mock-immunized animals. These results suggest that adoptive subcutaneous immunization with ex vivo rCPAF-pulsed BMDCs is an effective approach, comparable to that induced by UV-EB–BMDCs, for inducing robust anti-Chlamydia immunity.

Keywords: Chlamydia trachomatis, dendritic cell, CPAF, UV-EB, genital infection

INTRODUCTION

Chlamydia trachomatis is an obligate intracellular Gram-negative bacterium that is the leading cause of bacterial sexually transmitted disease worldwide (Morrison and Caldwell, 2002; Gottlieb et al., 2010). Development of an effective vaccine has been suggested to be the most promising and effective strategy to prevent this disease (Rank, 1999; Brunham and Rey-Ladino, 2005; Hafner and McNeilly, 2008); however, an efficacious anti-chlamydial vaccine has yet to be licensed for human use. Current Chlamydia vaccine research efforts in general are focused mainly on the development of recombinant subunit vaccines including, but not limited to, the major outer membrane protein (MOMP; Pal et al., 2005; Kari et al., 2009; Sun et al., 2009), other outer membrane proteins (OMPs; Olsen et al., 2010), polymorphic membrane proteins (PMPs; Yu et al., 2009; Eko et al., 2011), a immunogenic plasmid protein (PGP3; Chen et al., 2010), and the protease-like activity factor (CPAF; Li et al., 2007, 2008; Murthy et al., 2007).

Some of these recombinant subunit candidates induce enhanced chlamydial clearance and reduced upper genital tract pathologies, but none of them induce sterilizing protective immunity. For example, we have shown previously that immunization with soluble recombinant (r) CPAF induces significantly enhanced genital chlamydial clearance (Li et al., 2010), reduction of oviduct pathology (Murthy et al., 2007), and preservation of fertility following primary and/or repeated chlamydial challenge (Murthy et al., 2011). The lack of sterilizing immunity suggested that either a single subunit is inadequate as a vaccine, or the need for a more effective delivery system to optimize the effect of a single subunit candidate. Dendritic cells (DCs) are professional antigen presenting cells (APCs) and key players in determining the type and quality of T cell immune response. Immature DCs in the peripheral tissue are highly active in phagocytosis and processing microbial antigens and undergo a maturation process as they migrate to draining lymphoid tissues. The utility of ex vivo antigen-pulsed DCs as an effective inducer of protective immunity has been extensively studied for tumor immunity and infectious agents (Svensson et al., 1997; Siegemund and Alber, 2008). To this end, ex vivo Chlamydia-pulsed dendritic cell (DC) transfer has been shown to induce robust protective immunity comparable to that induced by a live Chlamydia infection (Su et al., 1998).

In this study, we evaluated whether subcutaneous immunization with DCs pulsed ex vivo with soluble (r) chlamydial
protease-like activity factor (rCPAF) would elicit an augmented immune response to induce sterilizing immunity against subsequent primary genital *C. muridarum* challenge. Bone marrow derived dendritic cells (BMDCs) pulsed *ex vivo* with rCPAF, with CpG as an adjuvant, displayed enhanced expression of activatory surface markers and secreted a high level of IL-12, an inducer of Th1 type immunity. Mice immunized subcutaneously with the rCPAF-pulsed BMDCs induced a high level of antigen-specific IFN-γ and anti-chlamydial antibody production, and induced significant protective immunity against genital *Chlamydia* infection.

**MATERIALS AND METHODS**

**RECOMBINANT PROTEINS, CHLAMYDIA, AND MICE**

The recombinant chlamydial proteins were purified as previously described (Li et al., 2008). Briefly, rCPAF constructs from *C. trachomatis* L2 genome with a 6X-Histidine tag (His) were cloned into pBAD vectors (Dong et al., 2004). The fusion proteins were expressed in *Escherichia coli* with t-arabinose as an inducer and extracted by bacterial lysis using sonication in a Triton X-100 lysis buffer. Ni–NTA agarose beads (Amer sham, NJ, USA) were used for purification of rCPAF. The fusion protein was concentrated using Centrifu plus YM-10 tubes (Millipore, MA, USA), suspended in PBS with proteinase inhibitor cocktail (Roche, CA, USA), aliquoted, and then stored at −20°C. The purity of rCPAF was evaluated by SDS-polyacrylamide gel electrophoresis and by Western blot using antigen-specific murine antibodies. CpG (TCCATGACGTTCCT- GACGTT) was obtained from Sigma Genosys (St. Louis, MO, USA).

*Chlamydia muridarum* was grown on confluent HeLa cell monolayers. Cells were lysed using a sonicator (Fisher Scientific, PA, USA) and elementary bodies (EBs) purified on Renograffin gradients as described previously (Li et al., 2007). Aliquots of bacteria were stored at −70°C in sucrose–phosphate–glutamine (SPG) buffer.

Four to six week-old, female BALB/c mice were obtained from Charles River Laboratory (Bar Harbor, ME, USA). Mice were housed and bred at the University of Texas at San Antonio and provided food and water *ad libitum*. Animal care and experimental procedures were performed in compliance with the Institutional Animal Care and Use Committee (IACUC) guidelines.

**DENDRITIC CELL ISOLATION AND STIMULATION**

Bone marrow-derived dendritic cells were prepared as described (Su et al., 1998). In brief, 4–6 week-old female BALB/c mice were sacrificed and bone marrow was collected from both tibias and femurs. Erythrocytes were lysed by ammonium chloride treatment, and the cells immediately resuspended in Hank’s Gelatin Buffer. After washing the cells with HBSS buffer, BMDCs were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FBS, 4 mM l-glutamine, 10 U/ml penicillin and streptomycin, 0.5 mM 2-mercaptoethanol, 10 ng/ml each of IL-4, and granulocyte–macrophage colony stimulating factor (GM-CSF). On day 3, fresh 10 ng/ml each of IL-4 and GM-CSF was added to the culture. After 6 days of incubation, loosely adherent and non-adherent cells were harvested, washed, and resuspended in Hanks buffered salt solution (Gibco). A 2.3 ml Opti-Prep concentrate (Sigma) was added to 9.7 ml buffer [0.88% (wt/vol) NaCl, 1 mM EDTA, 0.5% (wt/vol) bovine serum albumin, 10 mM HEPES, pH 7.4, filter sterilized]. The cell suspension was gently layered on the top of 6 ml of the Opti-Prep mixture and centrifuged at 600 × g for 5 min. The interface was collected and washed, and the cells cultured for another 1–2 days for use and the enriched DCs (over 85% purity as determined by CD11c surface expression using flow cytometry) were used for experiments. For CpG, rCPAF + CpG, UV-EB + CpG stimulation, DCs were plated for 4 h in 24-well plates at 105 cells/ml in the presence of either 10 μg/ml rCPAF or UV-EB (at an MOI of 10) plus 30 μg/ml CpG, or with medium or 30 μg/ml CpG alone; the cells were then washed and incubated for 24 h. Cell supernatants were collected and stored at −70°C for cytokine profiling. Analyses for IL-12, IL-10, and IL-4 in the supernatant were carried out by ELISA.

**FLUORESCENT ANTIBODY STAINING AND FLOW CYTOMETRY**

Dendritic cells alone or DCs pulsed with different antigens were stained with FITC, phycoerythrin, or APC-conjugated antibodies (CD80, CD86, CD40, MHC II, and CD11c). Staining was done in PBS containing 5% FCS on ice for 20 min, washed three times with PBS, and flow cytometry analysis was performed with an LSR II instrument (BD Biosciences).

**ANTIGEN-SPECIFIC CD4+ T CELL RESPONSES**

Fourteen days after mice had been previously challenged and resolved *Chlamydia* genital tract infection, spleens (3–5) were removed, and splenocytes layered over a density gradient to collect mononuclear cells. CD4+ T cell populations were isolated using negative selection magnetic particles (Stem Cell Technologies, BC, Canada) and the purity was determined to be at least >90–95% of CD4+ T cells by flow cytometry using an PE-conjugated anti-CD4 monoclonal antibody (BD Biosciences, CA, USA). A separate pool of naïve splenocytes was prepared from PBS (mock) immunized animals and treated with mitomycin-C (25 μg/107 cells) for 20 min and used as a source of APCs. The purified CD4+ T cells (5 × 105 cells/well) were cultured with APCs (105 cells/well) at a 5:1 ratio in 0.2 ml and stimulated for 72 h in vitro with rCPAF (2 μg/well), UV-inactivated *C. muridarum* [106 inclusion forming units (IFU)/well, 10 MOI], the unrelated antigen hen egg lysozyme (HEL, 2 μg/well), or medium alone in culture plates. Supernatants from the culture wells were analyzed for IFN-γ, IL-10, and IL-4 production using BD OptELISA kits (BD Pharmingen, NJ, USA) as described previously.

**ADOPITIVE IMMUNIZATION AND CHLAMYDIA CHALLENGE**

Dendritic cells were incubated with IMDM medium, rCPAF (10 μg/ml), or UV-EB (ratio of 1:10) plus 30 μg/ml CpG at 37°C for 4 h, washed, and incubated in IMDM-10 containing GM-CSF for 24 h. Then rCPAF + CpG or UV-EB + CpG-pulsed DCs were collected and injected subcutaneously into mice at a concentration of 1 × 106 cells/mouse in 0.1 ml PBS twice at days 0 and 14. Seven days before *Chlamydia* challenge, mice were treated with 2.5 mg/mouse Depo-provera (Pfizer) to synchronize estrous. One month following the final vaccination, mice were challenged intravaginally with 5 × 104 CFU of *C. muridarum* in 5 μl of SPG.
buffer. Protection was assessed by quantifying the number of IFU recovered from vaginal swabs obtained on the indicated days after challenge. Entire genital tracts were removed from mice at day 80 after challenge and examined for the presence of hydrosalpinx, gross pathologic evaluation, and histopathology.

DETECTION OF ISOTYPE ANTIBODY LEVELS BY ELISA
Ten days after the final immunization, sera from the animals were analyzed by ELISA as described previously (Li et al., 2007). Microtiter plates were coated overnight with rCPAF (5 μg/ml) in sodium bicarbonate buffer (pH 9.5). Serial dilutions of sera were added to wells, followed by either goat anti-mouse IgG1 or IgG2a conjugated to alkaline phosphatase (Southern Biotechnology Associates, AL, USA). After washing, p-nitrophenyl phosphate substrate (Sigma, MO, USA) was added for color development and the absorbance at 405 nm measured using a μQuant microplate reader (Biotek Instruments, VT, USA). Reciprocal serum dilutions corresponding to 50% maximal binding were used to obtain titers.

VAGINAL C. MURIDARUM CHALLENGE AND DETERMINATION OF BACTERIAL SHEDDING
One month following the final vaccination, animals were challenged intravaginally (i.vag.) with 5 x 10^5 IFU. Vaginal chlamydial shedding was determined on the indicated days for a period of 30 days following challenge, by swabbing the vaginas of infected mice and incubating the swabbed material on HeLa cell monolayers grown on glass cover slips in 24-well plates. Cells were fixed with 2% paraformaldehyde and stained using a genus-specific rabbit monoclonal antibody and FITC labeled goat anti-rabbit secondary antibody. The number of inclusions was counted under a Zeiss Axioskop microscope, in 10 random mid-line fields for days 3–12 and over the entire cover slips for later time points. The absorbance at 405 nm measured using a μQuant microplate reader (Biotek Instruments, VT, USA). Reciprocal serum dilutions corresponding to 50% maximal binding were used to obtain titers.

ASSESSMENT OF GROSS PATHOLOGY IN THE UPPER GENITAL TRACT AND HISTOPATHOLOGY
Mice were euthanized at day 80 post-challenge, genital tracts collected, and the presence of gross hydrosalpinx was noted. The tissues were then photographed from a fixed distance at 6 megapixels using a Fuji F10 camera. Images were stored at high resolution and printed on sheets (A4 size) of paper. Dilatation of oviducts was scored as follows: the cross-sectional diameter of the oviducts was measured for the largest oviduct loop and the measurements for individual mice and mean ± SE for each group was determined as described previously. Genital tracts also were examined for the presence of hydrosalpinx, then fixed in 10% neutral formalin, and embedded into paraffin blocks. Serial horizontal sections (5 μm) were prepared and stained using hematoxylin and eosin (H&E). Stained sections were visualized using a Zeiss Axioskop microscope and scored in blinded fashion as described previously. Cellular parameters [polymorphonuclear cells (PMNs), mononuclear, and plasma cells] were individually scored as follows: 0, no significant presence of infiltration, 1, presence of infiltration at a single focus, 2, presence at two to four foci, 3, presence at more than four foci, or 4, confluent infiltration. Results are expressed as mean ± SD of scores from all animals in a group.

STATISTICAL ANALYSES
Sigma Stat (Systat Software Inc., San Jose, CA, USA) was used to perform all tests of significance. Student’s t-test was used for comparisons between two groups and analysis of variance (ANOVA) between multiple groups for vaginal chlamydial shedding and dilatation of hydrosalpinx. A chi-square test was used to compare the incidence of hydrosalpinx. p ≤ 0.05 was considered statistically significant. Microscopic oviduct pathology and histopathology scores were compared using ANOVA on ranks. All experiments were repeated at least twice, and each experiment was analyzed independently. In some experiments, where oviduct diameter data are shown as a composite of two experiments, the indicated significant difference holds true when the experiments are analyzed individually.

RESULTS

BMDcs PULSED WITH rCPAF PLUS CpG UP-REGULATED THE EXPRESSION OF SURFACE ACTIVATION MARKERS
Bone marrow-derived DCs were generated and pulsed ex vivo with IMDM alone, CpG, rCPAF + CpG, or UV-EB + CpG. After 24 h incubation, BMDCs were collected, and then examined by FACS analysis for expression of surface activation markers CD86, CD40, CD80, and MHC II. The purity of CD11c^+ BMDCs was 85.3% (Figure 1A, right panel), which was consistent with previous reports of 82–86% (Eaton et al., 2006). Only 0.6% of the BMDCs stained with an isotype control antibody (Figure 1A, left panel) confirming the specificity of the anti-CD11c antibody. As shown in Figure 1B, BMDCs incubated with IMDM displayed a baseline expression of CD86 (64.8%), CD80 (48%), CD40 (27.8%), and MHC II (65.2%) and, as expected, the isotype control antibody stained cells displayed minimal expression of each marker. BMDCs incubated with CpG alone displayed enhanced expression of CD86 (83.4%), CD80 (69.0%), CD40 (80.4%), and MHC II (90.1%). BMDCs incubated with rCPAF + CpG or UV-EB + CpG also displayed enhanced expression of CD86 (80.9 or 79.6%), CD80 (70.3 or 61.3%), CD40 (80.1 or 79.2%), and MHC II (89.1 or 86.1%). These results suggest that BMDCs pulsed ex vivo with the antigens, with CpG as an adjuvant, develop into a mature DC phenotype.

BMDcs PULSED WITH rCPAF PLUS CpG PRODUCE ELEVATED LEVELS OF IL-12
Dendritic cells play an essential role in priming the differentiation of naïve T cells to Th1, Th2, or Th17 (Perry et al., 1997; Allam et al., 2009). Interleukin-12 is an especially potent inducer of Th1 immunity (Huang et al., 1999; Lu and Zhong, 1999), which has been shown to play a dominant role in protection against genital chlamydial infection (Zhang et al., 1999). Therefore, we evaluated the production of IL-12 by BMDCs pulsed ex vivo with CpG, rCPAF + CpG, UV-EB + CpG, or medium after incubation for 24 h. The supernatants were assayed by ELISA for IL-12, IL-10, and IL-4 (Figure 2). All BMDCs displayed significantly (p ≤ 0.01) increased levels of IL-12, but not IL-10 or IL-4, when compared to BMDCs pulsed with medium alone. The levels of IL-12 production were enhanced comparably between the BMDCs treated with CpG (1435 ± 376 pg/ml), rCPAF + CpG (1028 ± 63 pg/ml), or UV-EB + CpG (1240 ± 80 pg/ml). These results suggest that
rCPAF + CpG-pulsed BMDCs are capable of priming a robust Th1 response.

**BMDCs PULSED WITH rCPAF PLUS CpG RESPOND TO INFECTION-SENSITIZED CD4+ T CELLS**

We also evaluated whether BMDCs pulsed ex vivo with rCPAF, UV-EB, or an unrelated antigen HEL were capable of processing and presenting antigens to elicit an antigen-specific IFN-γ response from Chlamydia-specific CD4+ T cells (Figure 3). BMDCs pulsed with rCPAF + CpG and UV-EB + CpG induced Chlamydia-specific CD4+ T cells to produce significantly ($p \leq 0.01$) higher levels of IFN-γ (1194 ± 309.5 and 8298 ± 586 pg/ml, respectively) compared to HEL pulsed BMDCs (39 ± 12.5 pg/ml). As expected, naive CD4+ T cells displayed minimal IFN-γ production upon culturing with BMDCs pulsed with the different antigens. These results suggest that BMDCs pulsed ex vivo with rCPAF + CpG process and present CPAF epitopes to CD4+ T cells, leading to the production of high levels of IFN-γ in an antigen-specific fashion.

**MICE IMMUNIZED SUBCUTANEOUSLY WITH EX VIVO ANTIGEN-PULSED BMDCS DISPLAY ROBUST ANTIGEN-SPECIFIC CYTOKINE AND ANTIBODY RESPONSES**

The induction of antigen-specific cytokine and antibody responses were evaluated following immunization with BMDCs pulsed ex vivo with rCPAF + CpG, UV-EB + CpG, or HEL + CpG. Fourteen days following initial immunization, splenic CD4+ T cells were purified, cultured with mitomycin-C treated APCs, stimulated in vitro with rCPAF or UV-EB, and IFN-γ production into the supernatant measured by ELISA. As shown in Figure 4A, mice vaccinated with rCPAF + CpG-BMDCs exhibited significantly ($p \leq 0.05$) greater rCPAF-specific IFN-γ production (1859 ± 216 pg/ml) than mice immunized with BMDCs...
pulsed with UV-EB + CpG or HEL + CpG. As expected, purified CD4⁺ T cells from animals vaccinated with BMDCs pulsed with UV-EB exhibited the greatest IFN-γ production upon stimulation with UV-EB (1953 ± 119 pg/ml). Purified CD4⁺ T cells from animals immunized with BMDCs pulsed with HEL + CpG (mock immunized) displayed minimal IFN-γ production upon stimulation with any chlamydial antigen, indicating the specificity of the measured cytokine responses. These results indicate BMDCs pulsed with rCPAF + CpG may elicit robust induction of antigen-specific IFN-γ production in vivo.

The serum antibody responses against rCPAF and UV-EB were measured 14 days after the last booster immunization. As shown in Figure 4B, animals vaccinated with BMDCs pulsed with rCPAF + CpG displayed elevated levels of anti-rCPAF IgG1 (416 ± 13.8) and IgG2a (639 ± 95.1) antibody. As expected, animals immunized with BMDCs pulsed with UV-EB + CpG exhibited high levels of anti-UV-EB IgG1 (858 ± 136.3) and IgG2a (2274 ± 111.5) antibody. Animals immunized with BMDCs pulsed with HEL + CpG (mock immunized) exhibited minimal anti-rCPAF and anti-UV-EB antibodies. Collectively, mice immunized with BMDCs pulsed with rCPAF displayed elevated levels of antigen-specific IFN-γ production and increased levels of anti-rCPAF IgG2a antibodies, suggesting the induction of a robust Th1 type response.

**IMMUNIZATIONS OF MICE WITH BMDCs PULSED WITH rCPAf PLUS CpG ENHANCES THE RESOLUTION OF GENITAL C. MURIDARUM INFECTION**

To determine the protective immunity induced by immunization with rCPAF-pulsed BMDCs, immunized mice were challenged intravaginally with C. muridarum 1 month after the second adoptive immunization. Vaginal chlamydial recovery was measured every third day post-challenge for a period of 30 days, vaccination with DC + HEL/CpG (unrelated antigen) served as the baseline...
for the degree of *Chlamydia* shedding, which was similar to mock-vaccinated mice over a 30-day period. As shown in Figure 5A,B, vaccination with rCPAF-pulsed BMDCs induced a significant reduction (*p < 0.05*) in bacterial shedding, with clearance of the infection in 50% of the mice as early as day 15, and in all (100%) mice by day 18 after challenge. In comparison, all of the HEL–BMDC (mock) immunized animals were still shedding *Chlamydia* on day 18 after challenge, and exhibited complete clearance on day 30 after challenge. As expected, animals immunized with UV-EB pulsed BMDCs began to resolve the infection as early as day 3 after challenge, and all (100%) mice in this group completely cleared the infection by day 18 after challenge. These results suggested vaccination with BMDCs pulsed with rCPAF + CpG did not induce resistance to infection, but mediated significantly accelerated chlamydial clearance leading to complete resolution of infection within the same time period as UV-EB pulsed BMDC immunized animals.

**IMMUNIZATION OF MICE WITH BMDCS PULSED WITH RCPAF PLUS CPG INDUCES PROTECTION AGAINST *C. MURIDARUM*-INDUCED UPPER GENITAL TRACT PATHOLOGY**

To determine the effect of immunization with rCPAF-pulsed BMDCs on development of *Chlamydia*-induced disease sequelae, the development of hydrosalpinx on day 80 after challenge was evaluated. Vaccination with BMDCs pulsed with rCPAF + CpG reduced the development of hydrosalpinx (17% bilateral) on day 80 after chlamydial challenge compared to animals immunized with BMDCs pulsed with HEL + CpG (mock immunized, 50% bilateral). BMDCs pulsed with UV-EB + CpG immunization induced comparable levels of protection against development of hydrosalpinx (33% bilateral) to those pulsed with rCPAF + CpG, following chlamydial challenge (Figure 6A).

Gross oviduct cross-sectional diameter also was measured as a quantitative indicator of the degree of hydrosalpinx. As shown in Figure 6B, animals immunized by BMDCs pulsed with HEL + CpG (mock immunized) displayed a high degree of oviduct dilatation (2 ± 0.39 mm) on day 80 after chlamydial challenge. In contrast, animals vaccinated with BMDCs pulsed with rCPAF + CpG displayed significantly reduced dilatation of oviducts (0.66 ± 0.21 mm). Animals vaccinated with UV-EB pulsed BMDCs also displayed significant reductions (1.21 ± 0.26 mm) in dilatation score.

The presence of inflammatory cellular infiltrates in the genital tract tissues was scored by microscopy (Figure 6C). Mice immunized with BMDCs pulsed with rCPAF + CpG or UV-EB + CpG displayed significant (*p < 0.05*) reductions in mononuclear cells (0.92 ± 0.25 and 1.08 ± 0.20, respectively) and plasma cells (0.42 ± 0.15 and 0.33 ± 0.11 respectively), compared to those immunized with BMDCs pulsed with HEL + CpG (mononuclear cells 2.1 ± 0.25, plasma cells 1.42 ± 0.35). These results indicate that vaccination with BMDCs pulsed with rCPAF + CpG...
induces robust protection against oviduct pathology and reduces inflammatory cellular infiltration.

**DISCUSSION**

Dendritic cells are central to induction of immunity to chlamydial genital tract infection, and potent immunity against genital tract reinfection, comparable to that induced by prior live chlamydial infection and has been achieved in the mouse model by immunization with DCs pulsed ex vivo with whole inactivated organisms (Su et al., 1998; Rey-Ladino et al., 2005). Thus, DC-based vaccination and immunotherapy provide a promising new tool for development of an effective *Chlamydia* vaccine. There have been positive efforts to improve DC-based vaccination approaches for cancer immunotherapy in the last decade. Several clinical trials of human DC-based vaccines are generating encouraging preliminary results demonstrating that there is an induction of tumor-specific immune responses and tumor regression (Santegoets et al., 2008; Le et al., 2010). These clinical DC-based vaccinations have been proved to be feasible and safe, although continued optimization is still required for broader cancer immunotherapy and potential applications against infectious diseases.

The present study shows that BMDCs pulsed ex vivo with rCPAF + CpG are effective in inducing optimal surface activation markers and functional maturation of DCs, including upregulated expression of CD86, CD80, CD40, MHC II; enhanced production of IL-12, but not IL-10 and IL-4, and an increased ability to process and present CPAF antigens to *Chlamydia*-specific CD4+ T cells. Moreover, protective immunity against genital infection can be achieved by subcutaneous immunization of mice with BMDCs pulsed ex vivo with rCPAF + CpG. These mice also displayed complete vaginal chlamydial clearance by day 18 post-challenge and a reduced incidence (50%) of hydroalphinx and histopathology, compared to clearance on day 30 and hydroalphin in 83% mice in HEL + CpG-BMDCs immunized mice. These results demonstrate that BMDCs pulsed with a recombinant chlamydial antigen may be used to induce robust anti-*Chlamydia* protective immunity at the genital mucosa.

Subcutaneous immunization with BMDCs pulsed ex vivo with rCPAF + CpG also induced robust antibody and cell mediated antigen-specific Th1 type responses and IFN-γ production, which resulted in the significant enhancement of genital chlamydial clearance and reduction of oviduct pathology. Although DC-based vaccines can efficiently present antigen to B cells and CD4+ T cells, the activation of CD4+ T cells by DCs can exert helper functions to enhance efficient antibody production, production of high-affinity antibodies through somatic hypermutation, and class-switching of antibodies (Tamura and Chiba, 2009). However, there was no evidence of resistance to initial infection, or a further enhancement in protective immunity compared to that induced by intranasal vaccination with soluble rCPAF + CpG (Cong et al., 2007) or rCPAF + IL-12 (Murthy et al., 2007) as demonstrated in our previous published studies. These results may suggest that the degree of priming obtained by DC vaccination and/or subsequent activation of CD4+ T cells may be comparable to that obtained following vaccination with soluble antigen. The lack of resistance to initial infection confirms and extends our prior findings that anti-CPAF antibodies are not capable of neutralizing chlamydial infectivity (Li et al., 2010). We hypothesize that this results directly from the fact that CPAF is a late-phase protein, produced only during the RB phase, and not present in the infectious EB phase of the chlamydial organism. Additionally, DC immunization may induce robust antigen-specific IFN-γ responses, but did not result in superior protective immunity when compared to soluble rCPAF immunization. This may suggest that cell mediated immunity is only capable of inducing enhanced and complete clearance around days 15–18 after genital *C. muridarum* challenge. This also is supported by clearance of infection in a similar time period following immunization with BMDCs pulsed with inactivated whole chlamydial organisms. However, it cannot be excluded that BMDC immunization administered intravenously as in previous reports (Su et al., 1998; He et al., 2005), instead of subcutaneously as in this study, may have resulted in chlamydial clearance at earlier time periods. In the previous reports, the BMDC immunization was delivered via the retro-orbital plexus (Su et al., 1998), a method that has been considered invasive and less favorable in recent years. Given the promising potential of CPAF in inducing antichlamydial protective immunity, it may be worthwhile to evaluate intravenous immunization with rCPAF-pulsed BMDCs via the tail vein in future studies.

Collectively, BMDCs pulsed ex vivo with rCPAF plus CpG induced enhancements in genital chlamydial clearance and reduction of oviduct pathology comparable to our past studies with soluble rCPAF + CpG intranasal vaccination (Murthy et al., 2007; Li et al., 2010). These results confirm and extend our previous reports on the efficacy of CPAF immunization in reducing *Chlamydia*-induced upper genital tract pathological sequelae. They also suggest that inducing chlamydial clearance at earlier time periods may require the inclusion of a chlamydial surface antigen, such as native MOMP which has been shown to induce antibodies that neutralize chlamydial infectivity (Pal et al., 2008; Kari et al., 2009), into a combination vaccine to achieve optimal anti-chlamydial protective immunity. Such a combination would display the benefit of MOMP mediated neutralizing antibody effects against specific serovars with partial resistance to infection resulting in reduced transmission, and cell mediated immunity induced by CPAF against multiple serovars and species of *Chlamydia*, resulting in reduction of oviduct pathological sequelae.

**ACKNOWLEDGMENTS**

This work has been supported by the National Institutes of Health grant 1RO1AI074860 and the Army Research Office of the Department of Defense under Contract No. W911NF-11-1-0136.

**REFERENCES**

Allam, J. P., Bieber, T., and Novak, N. (2009). Dendritic cells as potential targets for mucosal immunotherapy. *Curr. Opin. Allergy Clin. Immunol.* 9, 554–557.

Brunham, R. C., and Rey-Ladino, J. (2005). Immunology of *Chlamydia* infection: implications for a *Chlamydia trachomatis* vaccine. *Nat. Rev. Immunol.* 5, 149–161.

Chen, D., Lei, L., Lu, C., Galaleledeen, A., Hart, P. I., and Zhong, G. (2010). Characterization of Pgp3, a *Chlamydia trachomatis* plasmid-encoded immunodominant antigen. *J. Bacteriol.* 192, 6017–6024.

Cong, Y., Jupelli, M., Guentzel, M. N., Zhong, G., Murthy, A. K., and Arulanandam, B. P. (2007). Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances
Dendritic cell vaccination against Chlamydia

Li et al.

Protective immunity against genital Chlamydia muridarum infection. Vaccine 23, 3773–3780.

M. G., M. D., S., Y., and G., G. (2004). Intramolecular dimerization is required for the Chlamydia-secreted protease CPAF to degrade host transcriptional factors. Infect. Immun. 72, 3869–3875.

Eaton, K. A., Benson, L. H., Haeger, J., and Gray, B. M. (2006). Role of transcription factor T-bet expression by CD4+ cells in gastritis due to Helicobacter pylori in mice. Infect. Immun. 74, 4673–4684.

Eko, F. O., Okenu, D. N., Singh, U. P., F., J., C., T., G., S., and M. (2011). Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine 29, 3802–3810.

Gottlieb, S. L., Martin, D. H., Xu, Y., and Zhong, G. (2004). Intramol.-Vaccine and immune response to Helicobacter pylori in mice. Infect. Immun. 72, 4860–4869.

Hafner, L. M., and McNeilly, C. (2008). Vaccines for Chlamydia infections of the female genital tract. Future Microbiol. 3, 67–77.

Huang, J., Wang, M. D., Lenz, S., Gao, D., and Kaltenboeck, B. (1999). IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J. Immunol. 162, 2217–2226.

Huang, J., Wang, M. D., Lenz, S., Gao, D., and Kaltenboeck, B. (1999). IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J. Immunol. 162, 2217–2226.

Kari, L., Whitmire, W. M., Crane, D. D., Reeneau, N., Carlson, J. H., Goheen, M. M., Peterson, E. M., Pal, S., and de la Maza, L. M., and Caldwell, H. D. (2009). Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182, 8063–8070.

Le, D. T., Parcell, D. M., and Jaffe, E. M. (2010). Cellular vaccine approaches. Cancer J. 16, 304–310.

Li, W., Guentzel, M. N., Seshu, J., Zhong, G., Murthy, A. K., and Arulanandam, B. P. (2007). Induction of cross-killer protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin. Vaccine Immunol. 14, 1537–1544.

Li, W., Murthy, A. K., Guentzel, M. N., Chambers, J. P., Forshuber, T. G., Seshu, J., Zhong, G., and Arulanandam, B. P. (2008). Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J. Immunol. 180, 3375–3382.

Lu, H., and Zhong, G. (1999). Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect. Immun. 67, 1763–1769.

Morrison, R. P., and Caldwell, H. D. (2002). Immunity to murine chlamydial genital infection. J. Immunol. 168, 2741–2751.

Murthy, A. K., Chambers, J. P., Meier, P. A., Zhong, G., and Arulanandam, B. P. (2007). Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology and is highly dependent upon endogenous IFN-gamma production. Infect. Immun. 75, 666–676.

Murthy, A. K., Li, W., Guentzel, M. N., Zhong, G., and Arulanandam, B. P. (2011). Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine 29, 2519–2522.

Olsen, A. W., Theisen, M., Chris- tensen, D., Vollmann, E., and Andersen, P. (2010). Protection against Chlamydia promediated by a subunit vaccine (CTHI) compared with a primary intranasal infection in a mouse genital challenge model. PLos ONE 5, e10768. doi:10.1371/journal.pone.0010768.

Pal, S., Bravo, J., Peterson, E. M., and de la Maza, L. M. (2008). Protection of wild-type and severe combined immunodeficiency mice against an intranasal challenge by passive immunization with monoclonal antibodies to the Chlamydia trachomatis mouse pneumoni- tis major outer membrane protein. Infect. Immun. 76, 5581–5587.

Pal, S., Peterson, E. M., and de la Maza, L. M. (2005). Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect. Immun. 73, 8153–8160.

Perry, L. L., Feilker, Z., and Caldwell, H. D. (1997). Immunity to Chlamydia trachomatis is mediated by helper 1 cells through IFN-gamma-dependent and -independent pathways. J. Immunol. 158, 3344–3352.

Rank, G. R. (1999). Chlamydia Intra-cellular Biology, Pathogenesis and Immunity. Washington, DC: ASM Press, 239–296.

Radjadino, M., Koochesfahani, K. M., Zahari, M. L., Shen, G., and Brunham, R. C. (2005). A live and inactivated Chlamydia trachomatis mouse pneumonitis strain induces the maturation of dendritic cells that are phenotypically and immunologically distinct. Infect. Immun. 73, 1568–1577.

Santegoets, S. J., van de Eertwegh, A. J., van de Loodrecht, A. A., Scheper, R. J., and de Grijl, A. D. (2008). Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. J. Leukoc. Biol. 84, 1364–1373.

Siegemund, S., and Alber, G. (2008). Cryptococcus neoformans activates bone marrow-derived conventional dendritic cells rather than plasmacytoid dendritic cells and down-regulates macrophages. FEMS Immunol. Med. Microbiol. 52, 417–427.

Su, H., Messer, R., Whitmire, W., Fischer, E., Portis, J. C., and Caldwell, H. D. (1998). Vaccination against chlamydial genital tract infection by immunization with dendritic cells pulsed with live nonvi- able Chlamydiae. J. Exp. Med. 188, 809–8108.

Sun, G., Pal, S., Weiland, I., Peter- son, E. M., and de la Maza, L. M. (2009). Protection against an intranasal challenge by vaccines for- mulated with native and recombi- nant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine 27, 5020–5025.

Svensson, M., Stockinger, B., and Wick, M. J. (1997). Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presenta- tion to T cells. J. Immunol. 158, 4229–4236.

Tamura, T., and Chiba, J. (2009). Production of antibodies against multibar membrane proteins expressed in human tumor cells using den- drritic cell immunization. J. Biomed. Biotechnol. 2009, 673098.

Yu, H., Jiang, X., Shen, C., Karunakaran, K. P., and Brunham, R. C. (2009). Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models. J. Immunol. 182, 6102–6108.

Zhang, D., Yang, X., Lu, H., Zhong, G., and Brunham, R. C. (1999). Immunity to Chlamydia trachoma- tis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte macrophage colony-stimulating fac- tor and interleukin-12 production and with dendritic cell-like maturation. Infect. Immun. 67, 1606–1613.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 05 October 2011; paper pending published: 01 November 2011; accepted: 23 November 2011; published online: 08 December 2011.

Citation: Li W, Murthy AK, Chaganty JP, Guentzel SN, Seshu J, Chambers JP, Zhong G and Arulanandam BP (2011) Immunization with den- dritic cells pulsed ex vivo with recombinant chlamydial protease-like activ- ity factor induces protective immunity against genital Chlamydia muridarum challenge. Front. Immunol. 2:73. doi:10.3389/fimmu.2011.00073

This article was submitted to Frontiers in Microbiology, a specialty of Frontiers in Immunology.

Copyright © 2011 Li, Murthy, Chaganty, Guentzel, Seshu, Chambers, Zhong and Arulanandam. This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License, which permits non-commercial use, distribution, and repro- duction in other forums, provided the original authors and source are credited.